Harmony Biosciences Holdings Net Income
| HRMY Stock | USD 36.00 0.01 0.03% |
As of the 16th of February 2026, Harmony Biosciences retains the Risk Adjusted Performance of 0.0911, downside deviation of 2.05, and Market Risk Adjusted Performance of 0.2352. Harmony Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Harmony Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.9001 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 167.3 M | 175.7 M | |
| Net Income Applicable To Common Shares | 208.7 M | 219.1 M | |
| Net Income | 167.3 M | 175.7 M | |
| Net Income Per Share | 2.30 | 2.42 | |
| Net Income Per E B T | 0.87 | 1.14 |
Harmony | Net Income | Build AI portfolio with Harmony Stock |
The evolution of Net Income for Harmony Biosciences Holdings provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Harmony Biosciences compares to historical norms and industry peers.
Latest Harmony Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Harmony Biosciences Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Harmony Biosciences financial statement analysis. It represents the amount of money remaining after all of Harmony Biosciences Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Harmony Biosciences' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harmony Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 145.49 M | 10 Years Trend |
|
Net Income |
| Timeline |
Harmony Net Income Regression Statistics
| Arithmetic Mean | 16,788,691 | |
| Coefficient Of Variation | 604.43 | |
| Mean Deviation | 86,197,483 | |
| Median | (39,898,000) | |
| Standard Deviation | 101,475,121 | |
| Sample Variance | 10297.2T | |
| Range | 333.4M | |
| R-Value | 0.75 | |
| Mean Square Error | 4835.6T | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | 15,034,387 | |
| Total Sum of Squares | 164755.2T |
Harmony Net Income History
Other Fundumenentals of Harmony Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Harmony Biosciences Net Income component correlations
Harmony Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Harmony Biosciences is extremely important. It helps to project a fair market value of Harmony Stock properly, considering its historical fundamentals such as Net Income. Since Harmony Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Harmony Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Harmony Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harmony Biosciences. Market participants price Harmony higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Harmony Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.101 | Earnings Share 3.17 | Revenue Per Share | Quarterly Revenue Growth 0.287 | Return On Assets |
Harmony Biosciences's market price often diverges from its book value, the accounting figure shown on Harmony's balance sheet. Smart investors calculate Harmony Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Harmony Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Harmony Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harmony Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harmony Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Harmony Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Harmony Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Harmony Biosciences.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Harmony Biosciences on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Harmony Biosciences Holdings or generate 0.0% return on investment in Harmony Biosciences over 90 days. Harmony Biosciences is related to or competes with Vera Therapeutics, Aurinia Pharmaceuticals, Celldex Therapeutics, MannKind Corp, Janux Therapeutics, Biohaven Pharmaceutical, and Abcellera Biologics. Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for... More
Harmony Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Harmony Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Harmony Biosciences Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.05 | |||
| Information Ratio | 0.0699 | |||
| Maximum Drawdown | 10.69 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 3.38 |
Harmony Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Harmony Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Harmony Biosciences' standard deviation. In reality, there are many statistical measures that can use Harmony Biosciences historical prices to predict the future Harmony Biosciences' volatility.| Risk Adjusted Performance | 0.0911 | |||
| Jensen Alpha | 0.1442 | |||
| Total Risk Alpha | 0.0513 | |||
| Sortino Ratio | 0.0666 | |||
| Treynor Ratio | 0.2252 |
Harmony Biosciences February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0911 | |||
| Market Risk Adjusted Performance | 0.2352 | |||
| Mean Deviation | 1.46 | |||
| Semi Deviation | 1.75 | |||
| Downside Deviation | 2.05 | |||
| Coefficient Of Variation | 946.55 | |||
| Standard Deviation | 1.95 | |||
| Variance | 3.82 | |||
| Information Ratio | 0.0699 | |||
| Jensen Alpha | 0.1442 | |||
| Total Risk Alpha | 0.0513 | |||
| Sortino Ratio | 0.0666 | |||
| Treynor Ratio | 0.2252 | |||
| Maximum Drawdown | 10.69 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 3.38 | |||
| Downside Variance | 4.2 | |||
| Semi Variance | 3.06 | |||
| Expected Short fall | (1.61) | |||
| Skewness | (0.56) | |||
| Kurtosis | 1.31 |
Harmony Biosciences Backtested Returns
At this stage we consider Harmony Stock to be very steady. Harmony Biosciences holds Efficiency (Sharpe) Ratio of 0.0575, which attests that the entity had a 0.0575 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Harmony Biosciences, which you can use to evaluate the volatility of the firm. Please check out Harmony Biosciences' Downside Deviation of 2.05, market risk adjusted performance of 0.2352, and Risk Adjusted Performance of 0.0911 to validate if the risk estimate we provide is consistent with the expected return of 0.11%. Harmony Biosciences has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.87, which attests to possible diversification benefits within a given portfolio. Harmony Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Harmony Biosciences is expected to follow. Harmony Biosciences right now retains a risk of 1.94%. Please check out Harmony Biosciences potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Harmony Biosciences will be following its current trending patterns.
Auto-correlation | -0.08 |
Very weak reverse predictability
Harmony Biosciences Holdings has very weak reverse predictability. Overlapping area represents the amount of predictability between Harmony Biosciences time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Harmony Biosciences price movement. The serial correlation of -0.08 indicates that barely 8.0% of current Harmony Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | -0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.54 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Harmony Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Harmony Biosciences Holdings reported net income of 145.49 M. This is 57.37% lower than that of the Pharmaceuticals sector and 107.71% higher than that of the Health Care industry. The net income for all United States stocks is 74.52% higher than that of the company.
Harmony Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Harmony Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics of similar companies.Harmony Biosciences is currently under evaluation in net income category among its peers.
Harmony Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Harmony Biosciences from analyzing Harmony Biosciences' financial statements. These drivers represent accounts that assess Harmony Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Harmony Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.5B | 3.3B | 1.9B | 2.0B | 1.8B | 1.8B | |
| Enterprise Value | 2.4B | 3.2B | 1.8B | 1.7B | 1.9B | 2.5B |
Harmony Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Harmony Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Harmony Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Harmony Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Harmony Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Harmony Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Harmony Biosciences' value.| Shares | Arrowstreet Capital Limited Partnership | 2025-06-30 | 906.9 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 758.9 K | Goldman Sachs Group Inc | 2025-06-30 | 720.7 K | Massachusetts Financial Services Company | 2025-06-30 | 644.5 K | Boston Partners Global Investors, Inc | 2025-06-30 | 605.5 K | Venbio Partners Llc | 2025-06-30 | 489.2 K | Charles Schwab Investment Management Inc | 2025-06-30 | 437.8 K | Northern Trust Corp | 2025-06-30 | 433.9 K | Nomura Holdings Inc | 2025-06-30 | 422.9 K | Blackrock Inc | 2025-06-30 | 6.7 M | Valor Management Llc | 2025-06-30 | 6.6 M |
Harmony Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 1.57 B | ||||
| Shares Outstanding | 57.6 M | ||||
| Shares Owned By Insiders | 12.13 % | ||||
| Shares Owned By Institutions | 88.36 % | ||||
| Number Of Shares Shorted | 5.68 M | ||||
| Price To Earning | 293.37 X | ||||
| Price To Book | 2.48 X | ||||
| Price To Sales | 2.51 X | ||||
| Revenue | 714.73 M | ||||
| Gross Profit | 641.74 M | ||||
| EBITDA | 233.41 M | ||||
| Net Income | 145.49 M | ||||
| Cash And Equivalents | 254.17 M | ||||
| Cash Per Share | 4.30 X | ||||
| Total Debt | 181.41 M | ||||
| Debt To Equity | 0.79 % | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 14.50 X | ||||
| Cash Flow From Operations | 219.82 M | ||||
| Short Ratio | 9.04 X | ||||
| Earnings Per Share | 3.17 X | ||||
| Target Price | 46.73 | ||||
| Number Of Employees | 268 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 2.07 B | ||||
| Total Asset | 999.2 M | ||||
| Retained Earnings | 2.22 M | ||||
| Working Capital | 404.17 M | ||||
| Net Asset | 999.2 M |
About Harmony Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Harmony Biosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.